某定点医院100例新冠肺炎患者Paxlovid用药情况分析

Analysis of the Use of Paxlovid in 100 Patients with COVID-19 Pneumonia at a Defined Hospital

目的统计某定点医院100例新冠肺炎患者使用奈玛特韦片/利托那韦片(Paxlovid)的具体情况,重点分析不良反应发生指数。方法收集2022年9月~2022年12月收治的曾使用Paxlovid治疗的100例新冠肺炎患者资料。对患者使用Paxlovid的不良反应发生指数及Paxlovid与其他药物之间潜在的药物相互作用(Drug-drug interactions,DDI)以及给药时机、用药疗程等进行回顾性分析。结果治疗期间共80例患者报告118例次不良反应,以血脂、肝酶异常为主(84例次,71.19%)(P<0.05);存在DDI的临床医嘱中,艾司唑仑出现的比例最高(34.00%)。共发现不合理用药73例次,Paxlovid占比最高(P<0.05)。结论某定点医院100例新冠肺炎患者使用Paxlovid的整体情况一般且不良反应和DDI发生率均较高,且不适当合并用药频繁出现,提醒临床谨慎用药。

OBJECTIVE The specific situation of Nematavir tablet/Ritonavir tablet(Paxlovid)used in 100 patients with COVID-19 pneumonia in a designated hospital was analyzed,with emphasis on the analysis of adverse reaction index.METHODS We collected data on 100 patients with COVID-19 pneumonia who were treated with Paxlovid between September 2022 and December 2022.Patients were retrospectively analyzed for Paxlovid timing during hospitalization,duration of therapy,adverse event index,and potential drug-drug interactions(DDI)between Paxlovid and other drugs.RESULTS During the treatment period,80 patients reported 118 adverse reactions,which were mainly abnormal in lipid and liver enzymes(84 cases,71.19%)(P<0.05);The proportion of Esther in clinical prescriptions with DDI(34.00%)A total of 73 cases of Paxlovid were found to be unreasonable(P<0.05).CONCLUSION The overall situation of using Paxlovid in 100 patients with COVID-19 pneumonia in a designated hospital is general,and the incidence of adverse reactions and DDI is high and inappropriate combined to remind clinical caution.